Real-World Dose Optimization and Titration of Esaxerenone: A Comprehensive Review for Clinicians

Abstract

Esaxerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), has emerged as a significant therapeutic option for hypertension and associated cardiovascular and renal diseases. This review synthesizes current evidence regarding real-world dose optimization and titration strategies for esaxerenone, drawing upon recent clinical trials, registry data, and guideline recommendations. Emphasis is placed on practical approaches for individualized therapy, risk mitigation, and maximizing clinical benefit, particularly within diverse patient populations encountered in daily practice. The review aims to empower healthcare professionals with actionable insights for integrating esaxerenone into contemporary management pathways.

Introduction

Hypertension and associated complications remain leading contributors to global morbidity and mortality, necessitating continual evolution in therapeutic strategies. Mineralocorticoid receptor antagonists (MRAs) such as esaxerenone offer a targeted approach for blood pressure reduction and end-organ protection. While randomized controlled trials (RCTs) have established the efficacy and safety profile of esaxerenone, translating these findings into real-world clinical practice requires nuanced understanding of dose optimization, titration, and patient selection. This article addresses the clinical rationale, evidence base, and practical considerations relevant to real-world implementation of esaxerenone therapy in adult patients with hypertension and related comorbidities.

Epidemiology / Disease Burden

Hypertension affects over 1.2 billion adults globally and is a principal risk factor for cardiovascular, cerebrovascular, and renal diseases. Despite availability of multiple antihypertensive classes, suboptimal blood pressure control persists in a substantial proportion of patients, particularly those with comorbid diabetes or chronic kidney disease (CKD). Aldosterone-mediated mineralocorticoid receptor activation is increasingly recognized as a central pathophysiological mechanism driving hypertension and end-organ damage, highlighting the need for potent and selective MRAs such as esaxerenone in clinical practice.

Pathophysiology

The mineralocorticoid receptor (MR) is a nuclear hormone receptor predominantly expressed in renal distal tubules, cardiovascular tissue, and the brain. Aldosterone binding to MR induces sodium reabsorption and potassium excretion, contributing to volume expansion and hypertension. Beyond volume regulation, MR activation promotes fibrosis, inflammation, and vascular remodeling, exacerbating cardiovascular and renal injury. Esaxerenone selectively antagonizes MR, inhibiting both genomic and non-genomic aldosterone effects, and offers a more favorable side effect profile compared to steroidal MRAs due to its non-steroidal structure and high receptor specificity.

Risk Factors

Patients with resistant hypertension, diabetes, CKD, and heart failure are at elevated risk for mineralocorticoid-driven target organ damage. Additional risk factors such as advanced age, obesity, and genetic predisposition further complicate management. Identification of these populations is critical for targeted esaxerenone therapy, as they are most likely to benefit from optimized MR blockade while also requiring careful monitoring for potential adverse effects, particularly hyperkalemia.

Clinical Features

Clinical manifestations of aldosterone excess include refractory hypertension, hypokalemia, metabolic alkalosis, and progressive organ dysfunction. In practice, many patients present with subclinical features, such as microalbuminuria or left ventricular hypertrophy, underscoring the importance of early intervention. Esaxerenone therapy, when appropriately titrated, can ameliorate these features by normalizing blood pressure, reducing proteinuria, and attenuating cardiac remodeling.

Diagnosis

Diagnosis of mineralocorticoid-driven hypertension typically involves assessment of blood pressure patterns, biochemical markers (e.g., plasma aldosterone concentration, renin activity, serum potassium), and evaluation for secondary causes. Baseline renal function and electrolyte assessment are mandatory prior to MRA initiation. For esaxerenone, ongoing monitoring is essential to guide dose adjustments and mitigate risks, particularly in patients with pre-existing renal impairment or those on concomitant renin-angiotensin-aldosterone system (RAAS) inhibitors.

Treatment & Management

Esaxerenone is indicated for the treatment of hypertension and is increasingly used in diabetic nephropathy and heart failure. Initial dosing typically starts at 2.5 mg once daily, with titration to 5 mg or 10 mg based on therapeutic response and tolerability. Real-world studies demonstrate that individualized titration, guided by regular monitoring of blood pressure, renal function, and serum potassium, is critical for optimizing outcomes. Down-titration or temporary discontinuation may be required in the setting of hyperkalemia or acute kidney injury. Combination therapy with other antihypertensives, particularly RAAS inhibitors, can enhance efficacy but necessitates heightened vigilance for adverse effects.

Recent Advances / Emerging Therapies

Recent clinical trials and observational studies have expanded the evidence base for esaxerenone. Notably, the ESAX-HTN and ESAX-DN studies have demonstrated robust antihypertensive efficacy and renoprotective effects, with favorable safety profiles compared to traditional steroidal MRAs. Ongoing research is exploring esaxerenone\'s role in heart failure with preserved ejection fraction (HFpEF), resistant hypertension, and non-diabetic CKD, as well as head-to-head comparisons with eplerenone and spironolactone. Advances in biomarker-guided therapy and pharmacogenomics are poised to further refine dose individualization and risk stratification.

Guideline Recommendations

Contemporary hypertension and CKD guidelines increasingly endorse the use of non-steroidal MRAs in patients with inadequate blood pressure control or persistent proteinuria despite standard therapy. Guidelines recommend baseline assessment of renal function and serum potassium prior to initiation, with subsequent titration based on clinical response and laboratory monitoring. Esaxerenone is favored in patients at risk for steroidal MRA-associated adverse effects, such as gynecomastia or menstrual irregularities. Practical algorithms emphasize shared decision-making, close follow-up, and patient education to optimize adherence and minimize complications.

Conclusion

Esaxerenone represents a significant advance in the management of mineralocorticoid-driven hypertension and related comorbidities. Real-world dose optimization and titration require a patient-centered approach, integrating clinical assessment with evidence-based monitoring to achieve maximal therapeutic benefit while minimizing risks. Ongoing research and evolving guidelines will continue to shape best practices for esaxerenone use in diverse clinical scenarios, reinforcing its role as a cornerstone of modern antihypertensive therapy.